INGELHEIM, Germany & SINGAPORE--(BUSINESS WIRE)--Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. The panelists discuss the dramatic escalation ...